Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: The dexamethasone suppression test (DST) is the recommended first-tier test for suspected Cushing syndrome (CS). Missed dexamethasone intake or insufficient dexamethasone serum exposure may yield false positive results. Quantification of serum dexamethasone in DST samples may therefore improve test performance. Methods: Simultaneous quantification of dexamethasone and cortisol by liquid chromatography-tandem mass spectrometry in 400 DST serum samples (100 overt CS, 200 excluded CS, 100 adrenal incidentalomas with (possible) autonomous cortisol secretion, AI-ACS) randomly selected within the indication groups. The 2.5th percentile of dexamethasone in patients with excluded CS was considered the lower limit of normal (LLN). Results: Serum dexamethasone varied from undetectable to 20.2 ng/mL with a median of 4.8 ng/mL (95% CI 4.5-5.1 ng/mL). Dexamethasone was undetectable in only 16 patients (4%), suggesting non-compliance. The dexamethasone LLN was 1.8 ng/mL (4.6 nmol/L). Decreased glomerular filtration rate and diabetes mellitus were associated with higher serum dexamethasone concentration, while body mass index, sex, age, nicotine, and oral contraceptives had no significant effect. By excluding the 27 samples with dexamethasone <LLN and applying the method-specific cortisol cutoff of 2.4 µg/dL (66 nmol/L) to samples with suspected CS, the clinical specificity for CS increased from 67.5% to 92.4% while preserving 100% clinical sensitivity. Among 100 AI-ACS samples (defined by immunoassay), 4 samples had dexamethasone <1.8 ng/mL and 14 samples had cortisol <2.4 µg/dL, which excluded autonomous cortisol secretion. Conclusions: Quantification of dexamethasone and method-specific cortisol cutoffs in DST samples may reduce the false positive rate and lower the proportion of patients requiring further workup.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 3×
“8 mg/dL post Dex underwent further workup according to current guidelines (5, 11).”
MethodFassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566 · cited 4×
“8 mg/dL post Dex underwent further workup according to current guidelines (5, 11).”
BackgroundMethodInfluentialDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 1×
“Given the high clinical sensitivity of DST as a first-tier test, the low cutoff value chosen to exclude hypercortisolism leads to a relatively low clinical specificity (13).”
BackgroundUrine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors
Arlt, W., Biehl, M., Taylor, A. E., Hahner, S., Libé, R., Hughes, B. A., Schneider, P., Smith, D. J., Stiekema, H., Krone, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1565 · Cited by 458
Krasowski, M. D., Drees, D., Morris, C. S., Maakestad, J., Blau, J. L., & Ekins, S. (2014) · BMC Clinical Pathology · doi:10.1186/1472-6890-14-33 · Cited by 212 · cited 1×
“Dex in DST samples has historically been measured by radioimmunoassay (16–19) which is associated with lack of analytical specificity and cross-reactivity with structurally similar compounds (20, 21).”
BackgroundMEIKLE, A. W. (1982) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1982.tb00733.x · Cited by 201 · cited 1×
“First, we found an extremely broad range of Dex concentrations after administration of 1 mg at 11:00 PM the previous day; this finding is similar to earlier reports (10, 16).”
ResultWood, P. J., Barth, J. H., Freedman, D. B., Perry, L., & Sheridan, B. (1997) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/000456329703400302 · Cited by 190 · cited 3×
“First, we found an extremely broad range of Dex concentrations after administration of 1 mg at 11:00 PM the previous day; this finding is similar to earlier reports (10, 16).”
BackgroundResultUeland, G. Å., Methlie, P., Kellmann, R., Bjørgaas, M., Åsvold, B. O., Thorstensen, K., Kelp, O., Thordarson, H. B., Mellgren, G., Løvås, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0078 · Cited by 94 · cited 12×
“After establishing the new thresholds, Dex and cortisol were quantified in 100 DST samples from patients with AI-ACS.”
BackgroundMethodResultInfluentialDiagnosis of Cushing’s Syndrome in the Modern Era
Nieman, L. K. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.001 · Cited by 93
Recent Updates on the Diagnosis and Management of Cushing's Syndrome
Nieman, L. K. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.2.139 · Cited by 85
Research works printed but not linked: 21
- Lacroix, 2015, Cushing's syndrome, Lancet, 386, 913, 10.1016/S0140-6736(14)61375-1 · DOI · Paper page
- Pivonello, 2016, Complications of Cushing's syndrome: State of the art, Lancet Diabetes Endocrinol, 4, 611, 10.1016/S2213-8587(16)00086-3 · DOI · Paper page
- Barbot, 2020, Cushing's syndrome: overview of clinical presentation, diagnostic tools and complications, Best Pract Res Clin Endocrinol Metab, 34, 101380, 10.1016/j.beem.2020.101380 · DOI · Paper page
- Stalla, 2019, "The adrenal gland: central relay in health and disease - current challenges and perspectives 2018" - Cushing's disease, Exp Clin Endocrinol Diabetes, 127, 147, 10.1055/a-0664-7632 · DOI
- Loriaux, 2017, Diagnosis and differential diagnosis of Cushing's syndrome, N Engl J Med, 377, e3, 10.1056/NEJMc1705984 · DOI
- Nieman, 2015, Cushing's syndrome: Update on signs, symptoms and biochemical screening, Eur J Endocrinol, 173, M33, 10.1530/EJE-15-0464 · DOI · Paper page
- Guthrie, 1991, The impact of dexamethasone pharmacokinetics on the DST: a review, Psychopharmacol Bull, 27, 565
- Vilar, 2007, Pitfalls in the diagnosis of Cushing's syndrome, Arq Bras Endocrinol Metab, 51, 1207, 10.1590/S0004-27302007000800006 · DOI · Paper page
- Morris, 1986, Dexamethasone concentrations and the dexamethasone suppression test in psychiatric disorders, Br J Psychiatry, 148, 66, 10.1192/bjp.148.1.66 · DOI · Paper page
- O'Sullivan, 1997, Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects, Biol Psychiatry, 41, 574, 10.1016/S0006-3223(96)00094-7 · DOI
- Asvold, 2012, Association between posttest dexamethasone and cortisol concentrations in the 1 mg overnight dexamethasone suppression test, Endocr Connect, 1, 62, 10.1530/EC-12-0047 · DOI
- Soldin, 2009, Steroid hormone analysis by tandem mass spectrometry, Clin Chem, 55, 1061, 10.1373/clinchem.2007.100008 · DOI · Paper page
- Hempen, 2012, Dexamethasone suppression test: development of a method for simultaneous determination of cortisol and dexamethasone in human plasma by liquid chromatography/tandem mass spectrometry, Ann Clin Biochem, 49, 170, 10.1258/acb.2011.011004 · DOI · Paper page
- Hawley, 2018, Development of a rapid liquid chromatography tandem mass spectrometry method for the quantitation of serum dexamethasone and its clinical verification, Ann Clin Biochem, 55, 665, 10.1177/0004563218766566 · DOI
- Ceccato, 2020, Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation, J Endocrinol Invest, 43, 1105, 10.1007/s40618-020-01197-6 · DOI
- Reed, 1971, Influence of statistical method used on the resulting estimate of normal range, Clin Chem, 17, 275, 10.1093/clinchem/17.4.275 · DOI · Paper page
- Jackson, 2019, In this issue–May 2019: West Nile virus in horses. Treating horses with dexamethasone via nebulisation. Animal hoarding in NSW. Dangers of powdered washing soda for emesis in dogs. Pneumocystis in a dog following toceranib phosphate. Oxalate nephrosis in koalas, Aust Vet J, 97, 129, 10.1111/avj.12818 · doi:10.1111/avj.12818
- Bashir, 2020, Comparative safety, bioavailability, and pharmacokinetics of oral dexamethasone, 4-mg and 20-mg tablets, in healthy volunteers under fasting and fed conditions: a randomized open-label, 3-way crossover study, Clin Lymphoma Myeloma Leuk, 20, 768, 10.1016/j.clml.2020.06.022 · doi:10.1016/j.clml.2020.06.022
- Ritzel, 2015, ACTH after 15 min distinguishes between Cushing's disease and ectopic Cushing's syndrome: a proposal for a short and simple CRH test, Eur J Endocrinol, 173, 197, 10.1530/EJE-14-0912 · DOI · Paper page
- Rose, 1981, Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics, J Pharmacokinet Biopharm, 9, 1, 10.1007/BF01059339 · DOI
- Bancos, 2020, Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study, Lancet Diabetes Endocrinol, 8, 773, 10.1016/S2213-8587(20)30218-7 · DOI · Paper page
Cited by
Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
Self-citationDeutschbein, T., Reimondo, G., Di Dalmazi, G., Bancos, I., Patrova, J., Vassiliadi, D. A., Nekić, A. B., Debono, M., Lardo, P., Ceccato, F., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00100-0 · Cited by 205
Self-citationApproach to the Patient With Adrenal Incidentaloma
Bancos, I., & Prete, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab512 · Cited by 201
Hamidi, O., St-Jean, M., Lacroix, A., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag095 · Cited by 5
Metadata
- Authors
- Vogg, N., Kurlbaum, M., Deutschbein, T., Gräsl, B., Fassnacht, M., & Kroiss, M.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-05-17
- Volume
- 67
- Issue
- 7
- Pages
- 998-1007
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W3161394254
- Cited by
- 38
- References
- 12
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Deutsche Forschungsgemeinschaft (314061271)
- Bayerische Forschungsstiftung, Forschungsverbund FORTiTher (AZ-1365-18)
- German Excellence Initiative to the Graduate School of Life Sciences
- University of Würzburg
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. https://app.cochat.ai/papers/10.1093/clinchem/hvab056
- The paper
- Vogg, N., Kurlbaum, M., Deutschbein, T., Gräsl, B., Fassnacht, M., & Kroiss, M. (2021). Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvab056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.